More than nine million people die of cancer every year, demonstrating the urgent need to develop new medicines for patients in need. Yet traditional drug discovery is deeply inefficient. Drug developers spend, on average, 10-15 years and ~$2.6 billion to bring a single new drug to patients.
Immuneering is forging a new approach to drug discovery, fueled by bioinformatics and computational biology. For more than a decade we have helped leading pharmaceutical and biotech companies be faster and more productive by analyzing their data to elucidate mechanisms of action, identify biomarkers of response and find new targets. With a focus on rigorous and robust analyses of the highest quality, our services business continues thriving to this day.
Through these experiences, we gained a unique perspective on the mechanism of action of successful medicines, identifying common themes underlying those drugs that ultimately prove safe and effective. These counterintuitive lessons inspired us to develop our proprietary Disease Cancelling Technology.